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Abstract 
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the difficulties of 
establishing the credibility of trial-based and modeled claims for therapy interventions. Claims for interventions in behavioral health 
are no exception. A recent report by The Kennedy Forum emphasizes the need for a system of measurement-based care using validated 
scales to assess the need for and response to therapy.  To accomplish this, The Kennedy Forum proposed a core set of outcomes 
measures for behavioral health interventions. This core set provides the context for a proposed Behavioral Health Management Registry 
(BHMR). The purpose of this commentary is to describe the structure and content of the BHMR. The BHMR provides access to nine 
symptom rating scales for depression, mania, anxiety, PTSD, panic attacks, alcohol use, drug abuse and somatization, together with 
supplementary questions to capture socio-demographic characteristics of patients, pain experience and opioid use, medical marijuana, 
DSM-V criteria for PTSD diagnosis and sleep experience. As such, with patient and physician inputs over the course of treatment, the 
BHMR provides an evidence base for physician practices and health care decision makers to evaluate behavioral health interventions 
by tracking the cumulative response to therapy. In addition, the BHMR captures the perception of the patients as to whether or not 
their therapy has led to any substantive improvement in activity limitations, symptoms and quality of life. A particular focus of the 
BHMR is on monitoring and evaluating the impact of interventions on the overall experience of pain as well as tracking pain intensity 
and functional status by body location. This is important given the prevalence of pain and its association with conditions such as 
depression and anxiety. The BHMR can also support monthly reports to the practice to summarize patient throughput, the response to 
care by target pain patients and profiles of opioid use and abuse. The BHMR can be customized to meet the needs of individual practices. 
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Introduction 
A report released by The Kennedy Forum in 2015 Fixing 
Behavioral Health Care in America pointed to the fact that, 
although effective treatments exist, many Americans fail to 
receive the care they need due to ‘lack of access, poor quality 
care and ineffective coordination between medical and 
behavioral systems’ 1. The specialty mental health care system 
‘is underequipped to treat the vast number of people with 
mental health and substance use disorders’. The result is that 
primary care has become the principal de facto provider of 
behavioral health care, including substance abuse, with, 
inevitably, many if not the majority of patients receiving sub-
optimal care. In the four years since the Kennedy report was 
issued there appears to be little if any evidence for a 
substantive revision to the picture presented of the process of 
care. There is still a significant unmet need for coordination and 
improvement in care. The primary care focused model 
proposed by The Kennedy Forum remains central to the  
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Collaborative Care model, which is characterized by a primary 
care provider leading a team supported by a care manager, is 
access, in real time, to an evidence base that tracks patient 
engagement over the course of their treatment and monitors 
their response to therapy. This population-management 
perspective implies access to a patient registry where inputs to 
the registry database are generated by both patients (or their 
caregivers) and providers. Ideally, a care manager would 
coordinate inputs to the registry, evaluate responses and work 
with the care team to deliver effective interventions. At the 
same time, the registry would provide the basis for report 
generation, both for the individual patient and the practice. 
From the latter perspective, reports could be prepared for 
target patient groups and specific treatment modalities as well 
as providing a framework for cost-effectiveness assessment. 
Claims for competing interventions could be evaluated within a 
meaningful time frame with reports prepared for formulary 
evaluation. 
 
From a registry perspective, therefore, it is worth noting the 
following key policy recommendation from the Kennedy report: 
All primary care and behavioral health providers treating 
mental health and substance abuse disorders should implement 
a system of measurement-based care whereby validated 
symptom rating scales are completed by patients and reviewed 
by clinicians during encounters. Measurement-based care will 
help providers determine whether the treatment is working and 
facilitate treatment adjustments, consultations, or referrals for 
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higher intensity services when patients are not improving as 
expected. 
 
It is also worth emphasizing that measurement based care with 
the focus on validated PROs is considered best practice in 
providing optimal care. The ability to track response to therapy 
has been shown to lead to better outcomes through alerting 
physicians to possible treatment modifications promptly in real 
time as well as providing the basis for improved patient 
engagement. 
 
This is not to suggest, however, that there are not examples of 
the benefits of collaborative care in behavioral health. A 
number of these are detailed in the Kennedy report. The point, 
however, is that while it is possible to identify funded 
collaborative care interventions, the outreach is limited. The 
overwhelming majority of behavioral health (and physician 
groups together with specialist pain clinics) are not involved in 
measurement-based care, let alone collaborative care. The 
potential is limited because the opportunities are not in place 
to create financial incentives to facilitate creating a practice-
based registry to support measurement-based care 
 
The purpose of this commentary, given the recommendations 
of the The Kennedy Forum, is to propose a structure and 
associated metrics for a behavioral health registry: the 
Behavioral Health Management Registry (BHMR). 
 
Response Metrics 
The key to an effective registry is the choice of response metric 
that is built into the registry. As the Kennedy report points out 
‘The reality is that for many systems of care, the usual practice 
does not include regular use of validated and quantifiable rating 
scales’. This requirement has been recognized in two recent 
registry proposals detailed in commentaries published in 
INNOVATIONS in Pharmacy for medical marijuana dispensaries 
and the treatment of chronic pain 2 3 4. These proposed 
registries emphasize the critical role validated patient reported 
outcomes (PRO) instruments can play in monitoring outcomes. 
In the case of chronic pain the registry structure included not 
only overall pain assessments, for example chronic pain 
evaluations, but also validated instruments targeted to specific 
pain locations to assess the impact of therapy on pain intensity 
and functional status. At the same time, with the prevalence of 
opioids in chronic pain, the registry captured risk assessments 
for medication abuse, attitudes to medications as well as 
instruments to capture the impact of pain interventions on high 
prevalence co-morbidities such as depression and anxiety.  
 
The proposals for chronic pain and medical marijuana registries 
recognize, not only the increasing focus on outcomes as 
opposed to process measures by agencies such as CMS, but the 
fact that the evidence base to support intervention choice is 
limited. In the case of medical marijuana, with the possible 
exception of severe epilepsy, the evidence base,  judged against 
graded evidence standards, is essentially non-existent. 
Evidence for non-cancer pain in the  medium and long-term is 
also limited. The latest CDC Guidelines for Prescribing Opioids 
for Chronic Pain point out that evidence on long-term opioid 
therapy for chronic pain outside of end-of-life care remains 
limited, with insufficient evidence to determine long-term 
benefits versus no opioid therapy 5.  Although clinical trial data 
would suggest that risk for serious harms appear to be dose 
dependent, the evidence is typically short-term with most trials 
only reporting outcomes for 12 weeks or less. At best, the 
evidence would suggest that opioids are only moderately 
effective for pain relief and with small benefits for functional 
outcomes. This criticism applies with equal force to established 
opioid formulations as well as to the abuse deterrent opioid 
formulations that are entering the market place. Formulary 
committees cannot judge the competing merits claimed for 
abuse deterrent formulations in the absence of credible 
evidence, both from randomized clinical trials (RCTs) as well as 
practice based observational studies.  
 
There is, in the case of behavioral health, with the focus on 
mental health and substance abuse, considerable overlap in 
choice of metric with chronic pain. More importantly, and this 
is a feature of behavioral health interventions that is often 
overlooked, a substantial number of patients present with 
chronic non-cancer pain. The association of chronic pain with 
depression and anxiety is well established and it was for this 
reason that these potential co-morbidities were captured in the 
CPMR.   
 
Resources and Incentives 
A first step towards a more effective delivery of behavioral 
health services by specialist physician practices in co-ordination 
with other specialist providers, is to recognize the importance 
of incentives. With financial pressures on health care delivery, 
providers may reasonably argue that while a registry concept at 
the practice level has merit, there are insufficient resources 
available to support implementation. These could involve 
resources to proactively outreach to patients to support 
engagement and compliance in generating reports to track 
response to therapy as well as resources within the practice to 
support registry data entry and practice level reporting.  
 
If a practice is to adopt a registry platform then there has to be 
a prior assessment of the implications of this for practice 
management and the allocation of resources within that 
practice. If, for example, providers within the practice believe 
that a registry incorporating validated instruments can provide 
a more rigorous framework for treatment decisions and 
response monitoring, then they need to be assured that these 
more comprehensive and complex assessments can be 
resourced appropriately. In, for example, a fee-for- service 
environment where the primary revenue stream is from CPT 
billing to both Medicare/Medicaid and private insurers. The 
option of adopting a registry to support treatment decisions 
offers the practice the opportunity to-reassess how resources 
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might be more optimally assigned to target patient groups 
consistent with billing criteria. 
 
Again, in a fee-for-service environment, a critical measure of 
resource allocation would be the CPT billing profile as this is the 
primary determinant of the practice revenue stream. While this 
may be augmented by other revenue programs, notably those 
focused on the Medicare population (e.g., MIPS) the practice 
has to consider the opportunities for reimbursement where 
more detailed, comprehensive and time consuming patient 
encounters are considered justified. 
 
It is not the purpose here, however, to make any suggestions as 
to the appropriate billing arrangements. It is up to the practice, 
in consultation with their medical billing agency or their own 
billing staff to determine the possible options.   
 
The fact that the BHMR provides a platform for a behavioral 
health practice to evaluate resource allocation in its attempts 
to monitor and evaluate response to therapy, should not be 
seen as a vehicle for an across-the-board CPT up-coding. The 
principal focus of the BHMR is on tracking response to therapy. 
The emphasis is on duty of care. The presumption is that access 
to a structured registry environment provides treating 
physicians with tools that can support defensible and medically 
necessary treatment decisions. To achieve this  a practice needs 
the resources to devote to possibly more time-intensive yet 
evidence driven patient care; a personalized medicine platform.  
 
Behavioral Health Management Registry 
The proposed Behavioral Health Management Registry (BHMR) 
adopts a structure similar to that proposed for chronic pain and 
medical marijuana. The BHMR is practice focused and, in the 
first instance is designed to be adopted by behavioral health 
practices. That is, the structure incorporates selected PROs 
specific to behavioral health, supplemented by PROs specific to 
high prevalence co-morbidities in behavioral health practice 
(e.g., chronic pain) where the practice may intervene in its own 
right or refer patients for more specialized and intensive 
interventions. At the same time, inputs from the practice 
provider are designed to complement the PROs. The registry 
captures diagnosis (ICD-10-CM) codes, together with CPT codes 
specific to each visit made to the practice.  
 
Choice of Metrics 
There are a number of competing PROs for all conditions 
typically treated in a behavioral health practice. In the present 
case the task of selecting the appropriate PRO was made 
simpler by the Kennedy Foundation proposed ‘core set’ of 
validated outcome measures 6 7. The outcome measures 
selected for the registry cover the following domains: 
• Depression 
• Fatigue 
• Mania 
• Anxiety 
• PTSD (Post Traumatic Stress Disorder) 
• Panic attacks 
• Alcohol 
• Drug abuse 
• Somatization  
 
At the same time, the BHMR offers options for evaluating 
patients in more detail. Providers have the options of 
downloading a number of validated instruments for assessing 
both the presence of comorbid conditions as well as a more in-
depth assessment of the patient to confirm a provisional 
hypothesis. These cover: 
• Pain experience and likelihood of chronic pain 
• Pain intensity and functional status by pain location 
• Attitudes to pain medications 
• Opioid use and abuse risk 
• Constipation 
• Medication abuse (in course of treatment) 
• Medical marijuana use 
• Confirmatory PTSD evaluation 
• Sleep experience 
 
Pain Experience and Medication Abuse 
The association of pain with depression, together with the 
associated conditions of fatigue and anxiety is well established, 
together with its the impact on mood, appetite and sleep.. The 
role of behavioral health in addressing pain and its 
symptomology is recognized with the application of cognitive 
behavioral therapy and stress reduction therapy. These 
strategies may be applied as part of a pain management 
strategy that includes pharmacotherapy, including opioid 
prescribing.  
 
It is an open question, however, as to how well the experience 
of pain is assessed in behavioral health practices, to include the 
likelihood or continuing chronic pain and the baseline status 
and response of patients to behavioral therapy interventions by 
pain location.. There is little evidence for the application of 
validated instruments, not only to track response to therapy 
targeted at pain experience, but also to apply validated 
instruments to assess therapy responses that may be comorbid 
with pain, notably depression, anxiety, fatigue and sleep.  
 
To the extent that behavioral health practices rely on or 
supplement interventions with pain medications, it is important 
to provide, using validated instruments, an assessment of 
attitudes to pain medications, recent and current opioid use 
and an assessment of the likelihood or medication, in particular 
opioid abuse. At the same time, there needs to be an ongoing 
review of likely medication abuse by the patient.  
The recommendation by The Kennedy Forum is for the DAST-10 
instrument to be used to assess the patient’s potential for drug 
abuse, where abuse is defined as the use of prescribed or over 
the counter medications or drugs in excess of usage directions 
8 . While the DAST-10 has wide recognition, it was decided that 
as this instrument requires licensing and fee payments that 
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alternative instruments should be considered. To evaluate the 
potential for abuse, particularly in respect of pain medications 
it was decided to include, as default PROs, two instruments 
selected for the CPMR. These instruments are: (i) the short-
form Pain Medication Attitude Questionnaire (PMAQ-14) and 
(ii) the  Brief Risk Questionnaire (BRQ) 9. Given the ability to 
customize the BHMR, it is at the discretion of the user to include 
the DAST-10 in preference to the PMAQ-14 and the BRQ. 
 
The original 78-item version of the PMAQ developed by 
McCracken et al addressed seven areas of patient concern: 
addiction, perceived need, unfavorable scrutiny by others, 
adverse side effects, tolerance, mistrust in the prescribing 
doctor and withdrawal10. The short-form (PMAQ-14) proposed 
by Elander et al captured from the original 2 items from each  
of the seven PMAQ scale while retaining the content of the 
original scales. Confirmatory factor analysis demonstrated that 
the PMAQ-14 retained the original 7-factor structure with 
correlation analysis demonstrating that it retained the validity 
of the original constructs.  
 
As well as capturing attitudes to medications, the CPMR also 
addressed the question of the risk for prospective medication 
aberrant behavior. A number of risk assessment instruments 
were reviewed. These included the Pain Medication 
Questionnaire (PMQ), the Screener and Opioid Assessment for 
Patients with Pain - Revised (SOAPP-R; 5, 14 and 24 item 
versions), the Opioid Risk Tool (ORT) and, most recently, the 
Brief Risk Questionnaire (BRQ) 11 12 13 14.  
 
The BRQ is designed to predict opioid misuse, abuse, addiction 
and diversion. It was chosen in preference to other risk 
assessment instruments, specifically the Opioid Risk Tool (ORT) 
and the Screener and Opioid Assessment for Patients with Pain 
– Revised (SOAPP-R), because, on evidence available it is overall 
the most accurate with a sensitivity of 80% and a specificity of 
41%. Sensitivity in this context is the ability to identify those 
patients who later were observed to engage in opioid or 
medication misuse. The sensitivity of the BRQ, which is best 
seen not as a 12-item overall assessment of risk but as an 
evaluation of 12 areas of risk, also compared favorably in a 
head-to-head comparison with the structured clinical Brief Risk 
Interview (BRI) 15. 
 
Medical Marijuana 
It is also important to evaluate the role of botanical cannabis in 
patients being treated for behavioral health conditions. There 
is a limited and often conflicting evidence for the self-
medicating use of botanical cannabis in conditions such as 
depression, anxiety and PTSD. Of concern is the evidence for 
adverse psychiatric outcomes. In a recent review, for example, 
the authors conclude that the ‘known risks of marijuana … 
currently outweigh (the) unknown benefits for PTSD’ 16 .  
 
Given the uncertainties in the benefit-risk ratio of botanical 
cannabis in behavioral health, it is important to assess the 
experience of patients with botanical cannabis, whether it be 
sourced as part of a medical marijuana program certified by 
other providers or whether it is self-medicated. As well, it is 
important to assess the form of administration and dosing. 
These elements are also captured by the BHMR. 
 
Post-Traumatic Stress Disorder 
The PTSD checklist in the registry (PCL-5) is for DSM-V 
symptoms designed to assess provisionally  the likely presence 
of PTSD 17 . This is different from the PRO recommended in the 
Kennedy report which is based on the symptoms captured in 
the DSM-IV. Given changes to the number and description of 
symptoms, together with the revised scoring scale, the PCL-5 
scores are not compatible with the DSM-IV scoring.  This 20-
item validated scale, scored on a 5-point interval, is designed to 
give a provisional diagnosis of PTSD. It is not a stand-alone 
diagnosis and should be supplemented by a clinical assessment 
with a structured interview (e.g., the clinician-administered 
PTSD scale for DSM-V, CAPS-5 together with the Life Events 
Checklist) 18. The instrument is designed for symptoms in the 
past month and changes in these symptoms over time. 
Endorsed symptoms are those scored ‘moderately’ or higher. 
 
The PCL-5 can determine a provisional diagnosis in two ways: (i) 
DSM-V diagnostic rule where with at least 1 symptom from 
criterion B (questions 1 -5); 1 criterion C item (questions 6-7); 2 
criterion D items (questions 8-14) and 2 criterion E items 
(questions 15-20) or (ii) summing all items and using a cut-off 
score of 33. Change scores for the PCL-5 have yet to be 
determined. As a reference point, the DSM-IV PCL instrument 
suggests a minimum threshold of 5 points as determining 
response to therapy, with 10 points suggesting the change is 
clinically meaningful.  
 
The BHMR Platform: Reporting Structure 
The BHMR comprises two set of reports: one set completed by 
the patient the other by the provider’s office. These are an 
Initial Visit Patient Report completed on-line by the patient 
either prior to  or at their first provider visit together with an 
Initial Visit Patient Summary Report which scores and 
summarizes patient responses to the Initial Visit Report. 
Following the first visit, the patient completes a Patient 
Satisfaction and Management Plan Report. For all subsequent 
visits over the course of treatment, this process is repeated. The 
patient completes an on-line Follow-up Visit Report prior to the 
visit, with a scored Follow-up Visit Patient Summary Report sent 
to the provider, followed by a Patient Satisfaction Report that 
is retained within the registry but only provided to the practice 
as a monthly de-identified report for all initial visit respondents.  
 
Following each provider visit, the practice completes an Initial 
Visit Practice Report and for all subsequent visits a Follow-up 
Visit Practice Report. These reports are entered directly into the 
registry by the practice following each visit, complementing the 
monitoring and audit trail created by the patient visit reports. 
Initial Visit Patient Report 
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The Initial Visit Patient Report platform captures the 9 validated 
PROs recommended in the Kennedy report.  These are detailed 
in Table 1. At the same time, the BHMR offers, at the discretion 
of the provider, a further 10 validated PROs to detail pain 
experience and functional status by body location, opioid use 
potential abuse, PTSD and sleep.  
 
Table 1 
Core BHMR PRO Instruments 
Symptom or Comorbidity Comorbidities and Symptoms Score 
Somatization PHQ-15 Somatization Scale 19 Each item on the PHQ-15 is rated on a 3-point scale (0=not bothered at 
all; 1=bothered a little; 2= bothered a lot). The total score can range 
from 0 to 30, with higher scores indicating greater severity of somatic 
symptoms. 
Fatigue  Fatigue Severity Scale 20 21   Single score as average of 9 items; presence of fatigue ≥ 4. Note: mean 
2.3 (SD +/- 0.7 in normal healthy adults) 
Depression PHQ-9 Depression Scale 22   Score range 0 – 27 
Minimal Depression (score 0 – 4) 
Mild Depression (score 5 – 9) 
Moderate Depression (score 10 – 14) 
Moderately severe depression (score 15 – 19) 
Severe Depression (score 20+) 
Anxiety GAD-7 Anxiety Scale 23   Score range 0-28 
None or very mild anxiety (score 0 – 4) 
Mild anxiety (score 5 – 9) 
Moderate anxiety (10-15) 
Severe anxiety (16+)  
Mania Altman Self-Rating Mania 
Scale 24 
Comprises 5 sub-scales to cover (i) positive mood; (ii) self-confidence; 
(iii) sleep patterns; (iv) speech, (v) activity level. Each subscale scored 
from 1 = baseline to 5. A combined score of 6+ indicates a high 
probability of mania. 
Panic Attacks Panic Disorder Severity Scale 
25 The PDSS consists of seven items, each rated on a 5-point scale, which ranges from 0 to 4. The items assess panic frequency, distress during 
panic, panic-focused anticipatory anxiety, phobic avoidance of 
situations, phobic avoidance of physical sensations, impairment in 
work functioning, and impairment in social functioning. The overall 
assessment is made by a total score, which is calculated by summing 
the scores for all seven items. The total scores range from 0 to 28. A 
score of 9+ suggests the need for a formal diagnostic assessment. 
Post-traumatic Stress 
Disorder 
PCL-5 Checklist for PTSD  A 20-item stress symptom check list with each item scored  0 = not at 
all to 4 = extremely. Scored either according to DSM-5 criteria  by 
minimum number of items from each subscale or a cut-off of 33+ for 
the aggregate raw score 0 – 80. 
Alcohol Use Audit-C Alcohol Screen 26 A 3-item short version of AUDIT 10 item questionnaire to identify 
hazardous drinkers or those with active alcohol disorders. Scored on 
scale 0 -12. For males a score of 4+ is considered positive (females 3+). 
Drug Abuse  Drug Abuse Screening Test 
(DAST-10) (optional) 
A 10-item self-report instrument to assess involvement with drugs in 
past 12 months (not alcohol). Scores from 0 (no problems reported) t0 
9-10 severe and suggested intensive assessment. 
Drug Abuse (Attitude) Pain Medication Attitude 
Questionnaire – short form 
(PMAQ-14 
A short form of the 78-item PMAQ instrument. Retains the original 7 
subscales: addiction, perceived need, unfavorable scrutiny by others, 
adverse side effects, tolerance, mistrust in the prescribing doctor and 
withdrawal 
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Drug Abuse (Opioids) Brief Risk Questionnaire (BRQ) A 12-item instrument based on the BRI to predict opioid misuse, abuse, 
addiction and diversion of opioids – a broader array of behaviors than 
only predicting opioid addiction. 
 
The data elements and symptoms captured in the Initial Visit 
Patient Report are: 
• Socio-demographic status 
• Education level 
• Employment status 
• Current and previous overall health 
• Somatization (PHQ-15) 
• Fatigue (Fatigue Severity Scale) 
• Depression (PHQ-9) 
• Anxiety (GAD-7) 
• Mania (Altman Self-Rating Mania Scale) 
• Panic Attacks (Panic Disorder Severity Scale) 
• Post-Traumatic Stress Disorder (PTSD) 
o Stress Experience 
o Stress problems (PCL-5) 
• Alcohol Use (AUDIT-C) 
• Attitudes to medications 
• Likelihood of opioid abuse  
 
Initial Visit Patient Summary Report 
Once the patient has completed the report, it is immediately 
summarized and scored to create the Patient Initial Visit 
Summary Report. This is sent directly as a PDF report to the 
provider with a copy retained as part of the registry. The report 
can be accessed by the patient if required. The summary 
report scores the PRO instruments detailed in Table 1 
establishing a baseline for subsequent visit scores to establish 
response to therapy. Wherever possible the provider is 
informed as to whether or not any change in reported scores 
over baseline is considered clinically significant. 
 
Patient Satisfaction and Management Plan Report 
Following the initial visit the patients completes a Patient 
Satisfaction and Management Plan Report. This report follows 
from a similar report included as part of the CPMR. The 
satisfaction with care component covers: 
• Provider: satisfaction with care provided 
(thoroughness, time spent, overall quality of care) 
• Other Staff: satisfaction with care provided 
(reception staff, courtesy) 
• Practice Access: satisfaction with access provided  
(contacting office, waiting in office, parking) 
In each case, responses are on a five-point scale: excellent, 
good, just satisfactory, fair or poor.  
 
In addition, the patient completes after the initial visit a series 
of questions on the extent to which a behavioral health 
management plan has been provided and whether specific 
issues (e.g., fatigue, anxiety, depression, sleep) have been 
addressed. The patient is told that: A behavioral health 
management plan is a proposal for how your concerns are to 
be addressed; it might involve a proposal for a management 
team involving other specialist providers and nursing support, 
treatment options and possible use of pharmaceuticals, a 
timeline for treatment and the outcomes sought.  
 
The specific questions are: 
• Did your provider discuss and agree a treatment 
management plan with you? 
• Did your provider explain the importance of 
monitoring your response to therapy through 
continuing to report your health status on-line? 
• Did your provider discuss the possible involvement 
of other health professionals in your treatment? 
• Did your provider assess and recommend treatment 
for specific conditions identified in the initial 
evaluation of your health status (e.g., depression, 
anxiety, fatigue, panic attacks)? 
• Did your provider review possible prescription 
medication use as part of your management plan? 
• If the treatment of severe or chronic pain is part of 
your management plan, did your provider undertake 
a comprehensive assessment of pain status, to 
include pain intensity by body location and 
functional status?  
• Did your provider review the risks and benefits for 
you of proposed medication use?  
• Did your provider discuss the possible use of opioids 
in your treatment? 
• Did your provider caution you on the abuse potential 
of opioids? 
• If opioids were recommended, did your provider ask 
you to complete an opioid agreement? 
• Did your provider review the possibility of medical 
marijuana as part of your treatment management 
plan? 
• Did your provider discuss what the side effects of 
your treatment might be? 
• If you are not at work, did you discuss with your 
provider the possibility of returning to work? 
 
Initial Visit Practice Report 
Following the first encounter with the patient, the practice 
completes an on-line Initial Visit Practice Report. This report is 
designed to ensure: (i) that the registry captures those data 
that are entered in the CMS 1500 form or its equivalent; (ii) 
that medication use is reported accurately; and (iii) that the 
registry captures medication change or discontinuation and 
reasons for treatment discontinuation.  
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The data elements captured in the Initial Visit Practice Report 
are: 
• ICD-10-CM diagnosis codes 
• CPT codes  
• Therapy intervention(s) 
• Adverse Events 
• Medication utilization 
o Generic/brand name 
o Dose 
o Frequency 
o NDC code 
• Response to therapy 
• Referrals 
• Discontinuation of therapy 
 
Follow-up Visit Patient Report  
Prior to each follow-up visit, the patient completes a report to 
track the response to therapy. This report is shorter than the 
initial visit report as it captures only: (i) employment status and 
(ii) those PRO instruments for which a preliminary diagnosis 
has included the symptoms addressed: these are: (i) mania; (ii) 
panic attacks; and (iii) PTSD. The report also excludes attitudes 
to medications and the likelihood of opioid abuse. 
 
The Follow-up Visit Patient Report includes two questions 
which are repeated for all subsequent reports. These are: (i) 
reports of medication abuse and (ii) the patient assessment of 
response to therapy. In the former case, the patient reports on 
activities that are associated with medication abuse behavior. 
These are identical to those utilized in the CPMR. In the latter 
case, the PRO is the Patient Global Impression of Change 
(PGIC) instrument. This instrument is used widely in phase 3 
clinical trials and is a useful counterpoint to physician assessed 
response to therapy through validated PROs or simply 
professional assessment. 
 
Follow-up Visit Patient Summary Report 
Following all subsequent visits over the course of therapy, the 
responses to the Follow-up Visit Patient Report are scored and 
summarized for the provider. Again, they are captured in the 
registry with copies available on request to the patient. 
Importantly, the report also reports change in reported scores 
over baseline. This is a key input to assessing response to 
therapy. This format follows from that adopted by the CPMR.  
 
Follow-up Visit Practice Report 
The Follow-up Visit Practice Report is identical to the Initial 
Visit Practice Report with the exception of questions on 
response to therapy and reasons for therapy discontinuation. 
This retains a consistent or standardized response although 
the input may change (e.g., referrals, therapy modification) 
 
 
 
Supplementary Treatment Assessments 
As noted above, the BHMR allow the provider to assess 
therapy response at a more granular level with supplementary 
treatment evaluations. In this version of the BHMR the focus is 
on: (i) pain experience; (ii) medical marijuana; (iii) PTSD; and 
(iv) sleep.  In each case, the core BHMR platform allows the 
provider/patient either in an office environment or through an 
on-line link to access validated instruments and/or provide 
links to other registries.  
 
Pain Experience 
In large part because of the likelihood that a proportion of 
patients may report pain at more than one body location 
together with the difficulty of establishing prior experience 
with pain levels and pain locations, the BHMR, following the 
earlier CPMR, adopts a two-stage approach in evaluating 
baseline pain experience at the initial visit.  
 
In the first stage, patients are asked to detail their overall 
current pain experience together with their long-term 
experience of pain together and an assessment of their 
likelihood of their continuing to experience chronic pain. 
Current pain experience is defined in terms of (i) current pain 
on a standard visual analogue scale (VAS) where 0 = no pain 
and 10 = pain as bad as it could be; (ii) worst pain (VAS scale) 
in past two weeks; and (iii) average pain (VAS scale) over the 
past two weeks. These scores are combined to give a ‘pain 
intensity’ score. Patients then report their prior experience of 
chronic pain and the impact of their pain experience in the past 
six months on their activity status utilizing the validated 
Chronic Grade Pain Scale (CGPS) instrument27. This yields two 
categories of pain and disability and two categories of 
disability and its limiting effects. Finally, in this section, the 
algorithm proposed by Von Korff and Dunn is applied, with 
supplementary questions, to yield a risk score for the 
likelihood of continuing chronic pain 28.    
 
In the second stage, the focus is on pain intensity and 
functional status by body location. The BHMR, following the 
CPMR, identifies 13 pain locations and uses, where feasible, 
validated instruments to assess baseline pain intensity and 
functional status, tracking this over the course of treatment.  
In some cases the instrument only identifies functional status 
and, where this occurs, supplementary questions to measure 
pain intensity are included. This format provides the 
framework for tracking response to therapy. 
 
The BHMR, again following the CPMR also addresses the 
question of the likelihood of the patient experiencing 
neuropathic and fibromyalgic pain. Although a clinical 
diagnosis for neuropathic pain is the ‘gold standard’ a number 
of instruments have been proposed as symptom-based 
screening questionnaires for neuropathic pain. These 
instruments include the Self-completed Douleur 
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Neuropathique 4 (S-DN4) 29 , the ID-Pain 30, the pain detect 
questionnaire (PDQ) 31 and the Self-completed Leeds 
Assessment of  Neuropathic Symptoms and Signs (S-LANSS)32.    
For the purpose of the CPMR, the instrument selected was the 
ID-Pain with 6 sensory description items. The ID-Pain is short, 
it does not involve any patient self-examination and 
psychometrically it performs as well as the S-DN4 and PDG, 
and better than the S-LANSS 33.  Similarly, in the case of 
possible fibromyalgia, the patient is asked to report on the 
pain experience across multiple locations. Again, this is only 
indicative and is not a substitute for a clinical assessment.  
In the case of scores for hip pain, leg pain and foot or heel pain 
the assessment is in terms of (i) response to an item list (13 ) 
to give assessment of status by item but no overall score and 
(ii) pain intensity at present time, worst in previous two weeks 
and average over past two weeks. Again, there is the option 
for a client to choose a specific measures of pain and functional 
status for hip, leg or foot/heel pain (e.g., Oxford Hip Score 34) 
 
Table 2 details the 13 pain locations and the validated 
instrument that is proposed to assess functional status and, 
unless supplemented by a pain intensity score, the pain level 
reported. Scores are presented in the patient summary and 
sent to the provider both for the aggregate score as well as 
scores categorized to grade levels and subscales. As 
constipation is a common side effect of opioids, the provider 
has the option of utilizing the PAC-SYM questionnaire to 
monitor constipation experience and concerns. 
 
Table 2 
BHMR Pain Locations and Validated Instruments for Assessing Pain, Functional Status and Constipation 
 
Pain Location Instrument  Score 
Head Pain Migraine Disability Assessment Score 
(MIDAS)  35 
Grade 1: Little or no disability (score 0 – 5) 
Grade 2. Mild disability (score 6 – 10) 
Grade 3: Moderate disability (score 11 – 20) 
Grade 4: Severe disability (score 21+)  
Orofacial Pain Manchester Orofacial Pain and Disability 
Scale 36     
Physical Disability (score 0-14; 0 = least disability) 
Psychosocial Disability (score 0-38; 0 = least disability) 
Aggregate (score 0 – 52) 
Neck or Cervical Pain Copenhagen Neck Functional Disability 
Scale 37    
Aggregate score (0 – 30; 0 = no real complaints to 30 = 
real disability) 
Shoulder Pain Shoulder Pain and Disability Index 
(SPADI)38 
Aggregate score , total pain score and total disability 
score each as a percentage. Minimum detectable 
change 13 points (90% confidence) 
Elbow Pain Patient-Rated Elbow Evaluation (PREE)39 Pain subscale and Function subscales with total score 
with pain and functional problems weighted equally 
on a scale of 100 (0 = no disability) 
Wrist or Hand Pain  Patient- Rated Wrist Hand Evaluation 
(PRWHE)40  
Pain score (0=50), Function score (0-50) and total 
score (0= best score; 100 = worst score) 
Mid-back or Thoracic Pain Roland Morris Disability Scale 41 42      Score 0 – 24 (score ≥ poor outcome)  
Lower-back or Lumbar Pain Roland Morris Disability Scale Score 0 – 24; (score ≥ poor outcome) 
Hip Pain Items only No validated aggregate score or subscales 
Lower Abdominal Pain 
(Males) 
NIH-CPSI Abdominal Pain 
Questionnaire43 
Pain: score 0 – 21 (0 = least pain) 
Urinary Symptoms: score 0 – 10 (0 = no problem) 
Quality of Life: score 0 – 12 (0 = no impact) 
Lower Abdominal Pain 
(Females) 
NIH-CPSI Abdominal Pain Questionnaire  Pain: score 0 – 21 (0 = least pain) 
Urinary Symptoms: score 0 – 10 (0 = no problem) 
Quality of Life: score 0 - 12 ( 0 = no impact) 
Knee Pain International Knee Documentation 
Committee (IKDC) Questionnaire: 2000 
Subjective Knee Evaluation Form44 
Summing score (max 87) to give percentage. Score 100 
no limitations.  
Leg Pain Items only No validated aggregate score or subscales 
Foot or Heel Pain Items only No validated aggregate score or subscales 
Constipation PAC-SYM Questionnaire 45   Score averaged over 11 items (range 0 – 4) 
Average or mild constipation (score 0 – 0.9) 
Moderate constipation (score 1.0 – 2.9 
Severe or very severe constipation (Score 3.0+) 
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Medical Marijuana 
The extent to which behavioral health interventions might 
consider botanical cannabis as a treatment option is not 
known. Providers may consider specific formulations of 
botanical cannabis as an option for opioids although, as noted 
in an earlier series of commentaries, the evidence base for 
botanical cannabis in the core behavioral domains is limited. If 
botanical cannabis is considered then the provider would have 
to support the patient’s application for a medical marijuana 
card as well as recommending a dispensary that provided 
feedback to the provider on dosing regimen, form of 
administration and response to therapy. Few dispensaries, if 
any, are in a position to provide such feedback. 
 
Rather than relying upon feedback from a dispensary, the 
BHMR allows the provider access to a self-reporting series of 
questions that the patient completes after each dispensary 
visit. These details: 
• Name of dispensary 
• Visit date 
• Dosing (purchase) 
o Cannabis Strain/Brand name 
o THC mg/day 
o CBD mg/day 
o THC % 
o Frequency of administration (day) 
• Administration  
o Smoking 
o Vaporization 
o Tinctures 
o Ingestible oil 
o Edible 
o Topical 
 
Post -traumatic Stress Disorder 
Although to PCL-5 can be utilized to report ongoing response 
to PSTD treatment, the diagnosis provided by the PCL-5 score 
is only a provisional one. For providers who wish a more 
conclusive evaluation of PTSD the BHMR provides access to 
two instruments that can be downloaded for a detailed 
assessment. These are the CAP-5 and the LEC-5, reporting 
those results both as a checklist and summary scores for the 
registry. Reporting on the CAP-5 summary sheet gives an  
 
 
added dimension to evaluating treatment response to PTSD 
over the treatment timeframe. The DSM-V Criterion A items 
captured in the CAP-5 clinical interview  target the onset and 
duration of symptoms, subjective distress, impact of 
symptoms on social and occupational functioning, 
improvement in symptoms since a previous CAPS 
administration, overall response validity, overall PTSD severity, 
and specifications for the dissociative subtype 
(depersonalization and derealization). The CAP-5 downloaded 
for administration in the physician office, together with the 
LEC-5. This latter report asks respondents to detail their 
stressful experience(s) and to indicate whether or not they 
witnessed or learned about it.  Respondents are then asked to 
detail the single or worst event.   
 
Sleep Experience 
Although sleep experience is not considered a core domain, 
sleep experience is addressed in a number of items captured 
in the validated core instruments. If the provider wishes to 
assess sleep experience in more detail, a link is provided to the 
Rand Sleep scale. This asks patients: (i) time taken to fall 
asleep; (ii) hours of sleep and (ii) sleep patterns over the 
previous two weeks. 
 
Conclusions 
Evaluating and treating patients in the area of behavioral 
health is both time consuming and resource intensive. The 
implications of a long-term engagement between patient and 
provider point, as The Kennedy Forum emphasizes, the 
importance of a structured and validated assessment of 
patients and tracking of patient outcomes. Unless the practice 
can be recompensed by a revenue stream that supports a 
more intensive and evidence driven evaluation this will not 
occur. As recommended by the Kennedy Forum, the 
acceptance of validated instruments to support and monitor 
treatment decisions provides the opportunity for the practice 
providers to allocate the time to evaluate, develop 
management plans and monitor response to therapy. This is 
the role of the BHMR: to support the provision of more in-
depth and rigorous documentation in the duty and process of 
care.  
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